PAC-1, >=98% (HPLC), solid, solubility: <=2 mg/mL in deionized water

PAC-1, >=98% (HPLC), solid, solubility: <=2 mg/mL in deionized water

Stock Code: 3573519
Manufacturer Part No: P0115-5MG
Order Now for 7 day delivery
£125.78 (exc VAT) per 5MG
Quantity: - +

Biochem/physiol Actions


PAC-1 is a caspase 3 activator. Caspase activation is a key strategy in cancer therapy. Caspase 3 is a key executioner caspase and direct effector of apoptosis. Hallmark of many cancers is the circumvention of signal in the activation of executioner caspases and loss of apoptotic response. EC50 for caspase 3 activation = 0.33 µM and caspase 7= 4.5 µM. The IC50 for apoptosis induction = 0.92 µM. Elevated caspase 3 level in cancerous cell lines and tissues allows PAC-1 to selectively induce apoptosis in tissues.


Features and Benefits


This compound is featured on the Caspases page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.


General description


Procaspase-activating compound 1 (PAC-1) is an ortho-hydroxy N-acyl hydrazine compound. It is cytotoxic to a variety of cancer cells, such as lymphoma, leukaemia, breast carcinoma and glioblastoma. High doses of PAC-1 can promote neuroexcitation. It helps in the in vitro autoactivation of the proenzyme protease, which acts as a prototype for other protease activating compounds. PAC-1 dependant activation of procaspase-3 is associated with the chelation of zinc.


Packaging


5, 25 mg in glass bottle

Colourwhite
Quality Level100
InChI keyYQNRVGJCPCNMKT-LFVJCYFKSA-N
InChI1S/C23H28N4O2/c1-2-7-20-10-6-11-21(23(20)29)16-24-25-22(28)18-27-14-12-26(13-15-27)17-19-8-4-3-5-9-19/h2-6,8-11,16,29H,1,7,12-15,17-18H2,(H,25,28)/b24-16+
ManufacturerSIGMA-ALDRICH
Solubilitydeionized water: ≤2 mg/mL, DMSO: ≥10 mg/mL
Formsolid
Assay≥98% (HPLC)

There are no downloads for this product.